Search

Illumina Inc

Gesloten

SectorGezondheidszorg

187.92 -2.98

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

187.06

Max

195.43

Belangrijke statistieken

By Trading Economics

Inkomsten

-268M

-134M

Verkoop

68M

1.2B

K/W

Sectorgemiddelde

37.039

68.51

EPS

1.31

Winstmarge

-11.562

Werknemers

8,600

EBITDA

80M

330M

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

-0.66% downside

Dividenden

By Acuity

Volgende Winsten

29 okt 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

1.3B

30B

Vorige openingsprijs

190.9

Vorige sluitingsprijs

187.92

Nieuwssentiment

By Acuity

22%

78%

58 / 340 Rangschikking in Healthcare

Illumina Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 aug 2026, 23:06 UTC

Illumina Inc shares are lower in after-market trading following Thursday's close, despite an initial uptick. No specific news was identified to explain the decline.

5 aug 2026, 19:52 UTC

Correlated Moves

Illumina shares are lower following disappointing first-quarter results and broader market declines. ADP's report on weak job growth has added to cautious sentiment.

4 aug 2026, 19:31 UTC

Correlated Moves

Illumina Inc's shares are higher today, reflecting a broader market trend as the Russell 2000 Index also advances. The stock is near its one-month range high.

3 aug 2026, 20:03 UTC

News

Illumina shares are lower today as Citigroup maintains a Sell rating and raises its price target to $113 amid mixed analyst sentiment.

31 jul 2026, 23:06 UTC

News

Illumina Inc reported strong Q2 results and raised full-year guidance, yet shares declined in after-market trading from Friday's close of $202.95.

30 jul 2026, 23:41 UTC

News
Social Media

Illumina Inc shares declined in after-market trading despite strong second-quarter results and raised full-year EPS guidance, reflecting concerns over falling net income.

29 jul 2026, 23:26 UTC

Illumina Inc. shares declined after-market amid overall market volatility following the Federal Reserve's decision to maintain interest rates amid rising inflation concerns.

28 jul 2026, 19:46 UTC

News

Illumina Inc. is acquiring contingent payments from its merger with Treeline Biosciences to enhance integration. Shares are trading higher since Monday's close.

27 jul 2026, 23:26 UTC

Illumina Inc shares are lower in after-market hours, continuing a decline over the past three sessions with no specific news identified.

24 jul 2026, 17:46 UTC

Illumina Inc's shares are lower today, hitting a mid-morning low. Broader market sentiment may be affected by recent volatility in oil prices.

22 jul 2026, 19:31 UTC

News

Illumina Inc shares are lower amid a report citing stagnant sales and concerns over management's investment opportunities. The company may need acquisitions for growth.

21 jul 2026, 20:02 UTC

Correlated Moves
News

Illumina Inc's shares are higher, supported by broader market momentum and anticipation of upcoming earnings from major companies. The Russell 2000 Index also advanced.

20 jul 2026, 19:56 UTC

Correlated Moves

Illumina Inc shares declined during Monday's session, paralleling a drop in the ARK Genomic Revolution ETF amid broader market weakness.

17 jul 2026, 19:06 UTC

Illumina Inc shares are lower today amid broader market declines, particularly in technology and semiconductor stocks, following significant selling pressure in Asia.

16 jul 2026, 22:06 UTC

Illumina Inc shares are lower in after-market hours, tracking broader market declines amid geopolitical tensions and mixed economic indicators.

15 jul 2026, 18:51 UTC

Illumina Inc shares declined Wednesday, pulling back from earlier gains. No specific news was identified to explain this movement amid broader positive market trends.

14 jul 2026, 19:36 UTC

News

Illumina shares rise as Canaccord raises price target to $190.00, despite a patent ruling against the company in Germany.

10 jul 2026, 20:06 UTC

Correlated Moves

Illumina Inc shares are lower amid a broader decline in the biotechnology sector. Market volatility is heightened due to geopolitical tensions involving the U.S. and Iran.

9 jul 2026, 19:11 UTC

News
Correlated Moves

Illumina Inc. appointed Mike Sullivan as Chief Commercial Officer and Julie Coletti as Chief Legal Officer, contributing to a rise in shares amid sector gains.

8 jul 2026, 20:04 UTC

Correlated Moves

Illumina Inc shares are lower today, influenced by declines in the Life Sciences Tools & Services sector and a drop in the Russell 2000 Index.

7 jul 2026, 21:41 UTC

Illumina Inc. shares are higher in after-market trading, reflecting ongoing strength despite earlier session pullbacks and broader caution in the technology sector.

6 jul 2026, 19:52 UTC

Social Media
News

Evercore ISI raised its price target on Illumina to $200, maintaining an Outperform rating. Shares are trading higher amid positive sentiment and social media discussions.

2 jul 2026, 23:06 UTC

Correlated Moves

Illumina Inc shares declined in after-market trading, reflecting broader trends despite positive movements in European equity indices, including a rise in the DAX.

1 jul 2026, 20:03 UTC

News

Piper Sandler raised Illumina's price target to $200, contributing to shares trading higher today. The company also expanded its board with a new appointment.

30 jun 2026, 20:01 UTC

News
Social Media

Illumina Inc shares are lower as Roche launches a competing gene sequencer at a lower price, challenging Illumina's market share in genetic testing technology.

29 jun 2026, 23:16 UTC

Illumina Inc shares are lower in after-market trading, with no specific news identified to explain the movement. Broader U.S. equities show mixed performance.

26 jun 2026, 23:16 UTC

Illumina Inc shares are trading lower in after-market hours. Broader market concerns over rising interest rates and inflation may be influencing investor behavior.

25 jun 2026, 23:26 UTC

Illumina Inc shares are higher in after-market trading, reflecting strong performance above their 20-day moving average despite no specific news driving the move.

24 jun 2026, 20:02 UTC

News
Social Media

Illumina Inc. shares are higher amid gains in the Life Sciences Tools & Services sector. Barclays raised its price target to $145 from $122.

23 jun 2026, 22:46 UTC

Illumina Inc shares are higher in after-market trading, reflecting a notable advance since Tuesday's close and strong performance near the upper end of its one-month range.

Peer Vergelijking

Prijswijziging

Illumina Inc Prognose

Koersdoel

By TipRanks

-0.66% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 192.44 USD  -0.66%

Hoogste 230 USD

Laagste 113 USD

Gebaseerd op 16 Wall Street-analisten die 12-maands prijsdoelen bieden voor Illumina Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

16 ratings

8

Buy

5

Hold

3

Sell

Sentiment

By Acuity

58 / 340 Rangschikking in Gezondheidszorg

Nieuwssentiment

Zeer Sterk Bearish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Illumina Inc

Illumina, Inc. offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole-genome sequencing, genotyping, noninvasive prenatal testing, and product support services; and Galleri, a multi-cancer early detection test. In addition, the company is developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. The company serves genomic research centers, academic institutions, government laboratories, and hospitals, as well as pharmaceutical, biotechnology, commercial molecular diagnostic laboratories, and consumer genomics companies. It markets and distributes its products directly to customers, as well as through life-science distributors. Illumina, Inc. was incorporated in 1998 and is based in San Diego, California.
help-icon Live chat